Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

7,848 total articles

Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Super League Enterprise, Inc. announced a shareholder letter encouraging support for its acquisition of the Misfits Ads Division. The acquisition is expected to add profitable revenue, improve financial predictability, expand market share, and speed the company's path to sustainable cash-based EBITDA profitability. The transaction diversifies reven…

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Corporation presented new genetic data at the AACR Annual Meeting demonstrating that their MEK inhibitor, atebimetinib, rarely induces common resistance mutations in the MAPK pathway in treated patients. This supports the drug's potential for durable tumor shrinkage and improved survival in first-line pancreatic cancer. The company is a…

KBRA Affirms Ratings for Preferred Bank

KBRA Affirms Ratings for Preferred Bank

Kroll Bond Rating Agency (KBRA) has affirmed Preferred Bank's deposit and debt ratings with a stable outlook, highlighting the bank's robust profitability, high-yield loan portfolio, and efficient branch-light business model. The strong 2025 return on assets (ROA) of 1.84% underpins these ratings. Preferred Bank continues to serve a diverse custome…

Radware Announces 2026 Annual General Meeting

Radware Announces 2026 Annual General Meeting

Radware Ltd. announces its 2026 Annual General Meeting (AGM) to be held on May 25, 2026, at its New Jersey office. The agenda includes electing Class III directors, approving equity awards and bonus structure for the CEO, and reappointing the audit firm Kost Forer Gabbay & Kasierer. Financial statements for 2025 will also be presented and discussed…

Parsons Demand Response Technology to Optimize and Enable Los Angeles Department of Water & Power’s Operations and Strategic Plan

Parsons Demand Response Technology to Optimize and Enable Los Angeles Department of Water & Power’s Operations and Strategic Plan

Parsons Corporation has been selected by the Los Angeles Department of Water & Power (LADWP) to implement its Demand Response Management System (DRMS), significantly boosting LADWP's capacity to integrate distributed energy resources as part of its strategic plan to achieve 100% clean electricity by 2035 or sooner. This contract will enhance grid r…

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

Ascentage Pharma presented four preclinical studies at AACR 2026 demonstrating the efficacy and synergistic potential of its drug candidates Olverembatinib, APG-2449, and APG-5918 in treating various cancers. These findings support further clinical development and combination therapy strategies for hematologic malignancies and solid tumors, highlig…

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals announces FDA approval and commercial launch of Pimozide Tablets (1 mg and 2 mg), a generic version of Orap®, with 180-day exclusivity for first generic competition. The product targets a market with approximate annual U.S. sales of $3.1 million, supporting ANI's strategy to deliver limited competition generic products and expan…

Fiserv to Present at Upcoming Investor Conferences

Fiserv to Present at Upcoming Investor Conferences

Fiserv, Inc., a leading global provider of payments and financial services technology, announced its CEO Mike Lyons will present at major upcoming investor conferences in May, including the J.P. Morgan Global Technology, Media, and Communications Conference and the Bernstein Strategic Decisions Conference. The presentations will be webcast and avai…

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio announced updated interim data from its Phase 1/2 upliFT-D trial of PBFT02 for frontotemporal dementia with GRN mutations, showing reductions in brain atrophy and stabilization of plasma neurofilament levels in early-stage patients. Despite encouraging biomarker improvements and safety profile, the FDA requires a randomized controlled t…

Capital City Bank Group, Inc. Reports First Quarter 2026 Results

Capital City Bank Group, Inc. Reports First Quarter 2026 Results

Capital City Bank Group, Inc. reported first quarter 2026 net income of $15.8 million, $0.92 per diluted share, showing a 15% increase over the prior quarter despite slightly lower net interest income due to fewer calendar days. The bank achieved improved returns on assets and equity, stable credit quality, and strong deposit growth. Noninterest ex…

Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

Lumexa Imaging has appointed Kyle Lynch as its new Chief Growth Officer to lead enterprise growth strategies including joint ventures, acquisitions, and new developments. Lynch will also enhance sales productivity and standardize performance metrics across the company's outpatient imaging centers. This move aims to capitalize on strong sector trend…

Axalta Launches Zencore™ Cabinet Coating System

Axalta Launches Zencore™ Cabinet Coating System

Axalta Coating Systems has launched Zencore™, a new cabinet coating system designed to streamline manufacturing processes for high-volume operations in North America. Building on the technology of its premium Zenamel™ brand, Zencore™ reduces coating steps from three to two, improving throughput, cost efficiency, and reducing waste without compromis…

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

Sutro Biopharma presented encouraging preclinical data across several antibody-drug conjugate (ADC) programs, including STRO-004, STRO-006, and STRO-227, at the AACR 2026 meeting. STRO-004 demonstrated robust antitumor activity and favorable tolerability in solid tumor models, supporting advancement into clinical trials. Other pipeline candidates s…

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

Monopar Therapeutics announced Phase 3 trial results of ALXN1840 demonstrating greater neurologic improvement and reduced deterioration in Wilson disease patients with neurologic symptoms, compared to standard of care. The drug showed sustained benefits over multiple years and a favorable safety profile, supporting an FDA NDA submission planned for…

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

Immunocore Holdings plc announces that KIMMTRAK (tebentafusp-tebn) significantly improves five-year overall survival rates in first-line HLA-A*02:01 positive patients with metastatic uveal melanoma, doubling survival from 8% to 16%. The data, from the longest randomized Phase 3 trial in this disease and for any T cell engager in solid tumors, showc…

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Pharmaceuticals reported highly positive Phase 3 X-TOLE2 study results demonstrating significant seizure frequency reductions with azetukalner in patients with focal onset seizures, alongside promising 48-month long-term efficacy and safety data from the ongoing open-label extension. The data highlights azetukalner's potential as a preferred …